Seres Therapeutics (NASDAQ:MCRB) Earns “Sell (D+)” Rating from Weiss Ratings

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “sell (d+)” rating restated by equities research analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Separately, Canaccord Genuity Group increased their price objective on Seres Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $14.33.

Seres Therapeutics Stock Up 0.7%

Shares of MCRB stock opened at $17.85 on Friday. The stock has a fifty day moving average of $18.75 and a 200 day moving average of $13.24. Seres Therapeutics has a 52 week low of $6.53 and a 52 week high of $24.67. The firm has a market capitalization of $156.19 million, a price-to-earnings ratio of -1.61 and a beta of 0.19.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.72) by $0.45. Equities research analysts anticipate that Seres Therapeutics will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Seres Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MCRB. Vontobel Holding Ltd. increased its holdings in shares of Seres Therapeutics by 15.7% during the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company’s stock valued at $760,000 after acquiring an additional 147,671 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Seres Therapeutics by 221.8% during the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 48,013 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 89,995 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Seres Therapeutics during the second quarter valued at $249,000. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.